Sonoma Pharmaceuticals vs Sensus Healthcare
SNOA and SRTS side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How SNOA and SRTS compare
Sensus Healthcare is the larger company, worth 7.3 times as much as Sonoma Pharmaceuticals ($38.3M against $5.2M).
Sonoma Pharmaceuticals grew revenue faster over the last twelve months (38.7% versus −53.4% for Sensus Healthcare).
Sonoma Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −7.6% compared with −88.5% at Sensus Healthcare.
Sonoma Pharmaceuticals scores higher on the StockData Score (11 against 9 for Sensus Healthcare), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | SNOA | SRTS |
|---|---|---|
| Size and price | ||
| Market cap | $5.2M | $38.3M |
| Share price | $1.09 | $2.33 |
| Change, 1 year | −70.4% | −49.5% |
| Change, 5 years | −99.0% | −58.1% |
| Beta (5Y) | 1.93 | 1.13 |
| Employees | 250 | 60 |
| StockData Score | ||
| Total score | 11 (better) | 9 |
| Valuation score | 3 | 3 |
| Growth score | 3 (better) | 0 |
| Performance score | 2 (better) | 0 |
| Health score | 3 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.2× (better) | 2.2× |
| P/B | 0.8× (better) | 1.0× |
| FCF yield | −53.4% | −18.2% (better) |
| Fair value | $4.95 | $4.07 |
| Margin of safety | 78.0% (better) | 42.9% |
| Growth | ||
| Revenue growth (TTM) | 38.7% (better) | −53.4% |
| Revenue growth, 5Y average | 0.95% | 23.5% (better) |
| Profitability | ||
| Gross margin | 39.2% (better) | 36.4% |
| Operating margin | −3.3% (better) | −75.7% |
| Net margin | −7.6% (better) | −88.5% |
| FCF margin | −11.9% (better) | −39.8% |
| Return on equity | −34.5% (better) | −34.8% |
| Return on invested capital | −42.9% | −40.6% (better) |
| Financial health | ||
| Debt / equity | 0.01 (better) | 0.00 |
| Current ratio | 3.48 | 8.71 (better) |
| Altman Z-score | −14.20 | 5.37 (better) |
| Piotroski F-score | 3 | 5 (better) |
| Dividends and buybacks | ||
| Buyback yield | −81.9% | – |
| Shareholder yield | −81.9% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 2.3% | 22.2% |
| Held by insiders | 11.1% | 13.3% |
| Insider net buying, 12 months | – | $576K |
| Short interest, % of float | 1.6% | 1.6% |
Go deeper
- SNOA stock overview
- SNOA income statement
- SNOA valuation and score
- SRTS stock overview
- SRTS income statement
- SRTS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.